Mangiferin-6-O-berberine salt and preparation method and use thereof

Patent metadata

Field	Value
Publication number	US-10285969-B2
Application number	US-201715619936-A
Country	US
Kind code	B2
Filing date	Jun 12, 2017
Priority date	Jan 7, 2015
Publication date	May 14, 2019
Grant date	May 14, 2019

Abstract

The present invention provides a mangiferin-6-O-berberine salt and a preparation method thereof, and further provides a use of the mangiferin-6-O-berberine salt for the treatment of diabetics and other diseases as an AMPK activator.

First claim

What is claimed is:

1. A mangiferin-6-O-berberine salt, wherein the mangiferin-6-O-berberine salt has a structure as defined in the following formula (I):

wherein 0≤x≤4;
wherein spectrum data of 13 CNMR (400 MHz, DMSO-d6) δ of a mangiferin group of the mangiferin-6-O-berberine salt is as follows: 161.51 (C-1), 106.58 (C-2), 163.06 (C-3), 92.77 (C-4), 155.55 (C-4a), 103.74 (C-4b), 98.64 (C-5), 166.93 (C-6), 147.03 (C-7), 100.47 (C-8), 100.53 (C-8a), 154.37 (C-8b), 176.73 (C-9), 73.51 (C-1′), 70.34 (C-2′), 79.14 (C-3′), 70.34 (C-4′), 81.37 (C-5′), 61.27 (C-6′).

2. The mangiferin-6-O-berberine salt according to claim 1 , wherein x=2.

3. A preparation method for the mangiferin-6-O-berberine salt as defined in claim 1 , comprising:
(1) adding an alkaline sodium salt or a potassium salt into water to yield an alkaline aqueous solution of sodium salt or an alkaline aqueous solution of potassium salt, the solution having a concentration of 0.1%-2% (w/v);
(2) dissolving mangiferin into dimethyl sulfoxide to yield a mangiferin solution;
(3) slowly adding the mangiferin solution into the alkaline aqueous solution of sodium salt or the alkaline aqueous solution of potassium salt, fully stirring the solutions until the solutions are fully reacted at the temperature of 50° C.-100° C. to yield a mangiferin-6-O-sodium salt solution or mangiferin-6-O-potassium salt solution;
(4) adding berberine hydrochloride into water at the temperature of 50° C.-100° C. to yield a solution of berberine hydrochloride;
(5) fully mixing the solution of berberine hydrochloride with the mangiferin-6-O-sodium salt solution or mangiferin-6-O-potassium salt solution for full reaction, yielding a precipitate, filtering the precipitate to yield a solid; and
(6) drying the solid to yield the mangiferin-6-O-berberine salt.

4. The preparation method according to claim 3 , wherein a ratio of the mangiferin to the dimethyl sulfoxide is 1:0.2-5 (w/v).

5. The preparation method according to claim 3 , wherein a molar ratio of the mangiferin to the alkaline sodium salt or alkaline potassium salt is 1:0.5-1.

6. The preparation method according to claim 3 , wherein a molar ratio of the mangiferin-6-O-sodium salt or mangiferin-6-O-potassium salt to the berberine hydrochloride is 1:1.

7. The preparation method according to claim 3 , wherein the alkaline sodium salt or alkaline potassium salt is one or a mixture of more than two selected from the group consisting of sodium carbonate, sodium bicarbonate, potassium carbonate and potassium bicarbonate.

8. A drug, wherein the drug comprises the mangiferin-6-O-berberine salt as defined in claim 1 , and a pharmaceutically acceptable auxiliary material.

9. The mangiferin-6-O-berberine salt according to claim 1 , wherein: the mangiferin-6-O-berberine salt is an AMPK activator.

10. The mangiferin-6-O-berberine salt according to claim 9 , wherein the AMPK activator is used for a prevention or treatment of any one or more of the following diseases: diabetes, chronic diabetes complications, obesity, hyperlipidemia, insulin resistance, hyperinsulinemia, metabolic syndrome, hypertension, atherosclerosis, ischemic heart disease, myocardial hypertrophy, arrhythmia, heart failure, upper respiratory tract infection, chronic bronchitis, chronic obstructive pulmonary disease, asthma, pulmonary fibrosis, hepatitis, simple fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, alcoholic liver, alcoholic hepatitis, liver fibrosis, cirrhosis, prostatitis, pancreatitis, nephritis, nephrotic syndrome, hypertensive nephropathy, chronic renal insufficiency, rheumatic arthritis, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, cerebral infarction, memory impairment, Alzheimer's disease, infarct dementia, Parkinson's disease, tumors, muscle atrophy, and muscle weakness disease.

11. The mangiferin-6-O-berberine salt according to claim 10 , wherein the chronic diabetes complications comprise one or more diseases of: coronary heart disease, atherosclerosis, cerebrovascular disease; diabetic nephropathy, diabetic retinopathy; neuropathy; diabetic foot; diabetic maculopathy, cataracts, glaucoma, refractive changes, iris and ciliary body disease.

12. The drug according to claim 8 , wherein the drug is used for a treatment of breast hyperplasia, uterine polyps, prostatic hyperplasia, sexual dysfunction, infertility, eczema, and fatigue.

13. The mangiferin-6-O-berberine salt according to claim 1 , wherein x=1, 2, 3, or 4.

Assignees

• Changzhou Deze Medical Science Co Ltd
• Teng Houlei
• Wu Wei

Inventors

• Teng Houlei
• Wu Wei
• Zhang Jingzhuo
• Lin Zhe

Classifications

• A61K9/2027

  obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates · CPC title

• C07D455/04

  containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine · CPC title

• A61K31/352 Primary

  condensed with carbocyclic rings, e.g. methantheline  {(cannabinoids A61K31/658)} · CPC title

• A61K9/2059

  Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin · CPC title

• A61K9/2054

  Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title